This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed Inks Deal With athenaHealth on Brightree's eReferral
by Zacks Equity Research
ResMed's (RMD) wholly owned unit Brightree remains integral to the company's group for two full years with a consistent stretch of success.
ResMed Reports Positive Results for Bilevel PAP Device Study
by Zacks Equity Research
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
Illumina (ILMN) Grows on Innovation & Strategic Partnerships
by Zacks Equity Research
Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.
ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business
by Zacks Equity Research
Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.
Here's Why You Should Add ResMed (RMD) to Your Portfolio Now
by Zacks Equity Research
With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.
Top Ranked Momentum Stocks to Buy for May 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th:
ResMed (RMD) Up 6.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed Releases Positive U.S. & U.K. Study Data on COPD
by Zacks Equity Research
ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.
Hill-Rom (HRC) Earnings & Revenues Beat in Q2, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q2.
ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.
Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up
by Zacks Equity Research
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
LabCorp (LH) Beats on Q1 Earnings, Revenues, Lifts '18 View
by Zacks Equity Research
LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.
Medical Product Stock Earnings Roster for Apr 26: BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.
Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?
by Zacks Equity Research
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
Global Expansion and Product Launches to Aid ResMed's Growth
by Zacks Equity Research
ResMed (RMD) continues to benefit from solid sales of sleep devices, respiratory care devices, mask systems and software solutions globally.
Here's Why You Must Add ResMed (RMD) to Your Portfolio Now
by Zacks Equity Research
ResMed (RMD) boosts investor confidence on strength in Software-as-a-Service businesses as well as new mask products and devices.
ResMed (RMD) Rides High on Robust Global Growth & Innovation
by Zacks Equity Research
ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.
Why Is ResMed (RMD) Down 7.5% Since the Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.
LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.
Align Technology Banks on Global Growth, Competition Rife
by Zacks Equity Research
We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.